News - Orphalan SA

Company News

Why We Should Care About Rare Disease Research – Life Science Leader

Why We Should Care About Rare Disease Research “Access to life-saving or life-enhancing treatments should not be determined by the rarity of the disease; on the contrary, our greater understanding…

adminMay 9, 2023

Company News Press Release

Orphalan announces US commercial launch of Cuvrior™ for the treatment of Wilson disease

- Cuvrior™ now available in the US for the treatment of adult patients with stable Wilson disease who are de-coppered and tolerant to penicillamine - Oral administration offers dosing flexibility…

adminApril 20, 2023

Company News

Podcast: Naseem Amin, Orphalan CEO, discusses Wilson’s Disease and the potential advancements in its treatments on DNA Today

DNA Today is a multi-award-winning podcast and radio show exploring how genetics impacts our health. Host/Producer Kira Dineen interviews leaders in genetics including genetic counsellors, researchers, physicians, and patient advocates…

adminFebruary 6, 2023

Press Release

Orphalan announces publication of results from the CHELATE trial in The Lancet Gastroenterology & Hepatology

Trial supported Orphalan’s successful application to the United States Food and Drug Administration (FDA) for approval of Cuvrior™ (trientine tetrahydrochloride) for Wilson’s disease Paris, France 30 September, 2022 - Orphalan…

Minesh KothariSeptember 30, 2022

Press Release

Orphalan announces enrolment of the first five patients in the International Wilson’s Disease Patient Registry (“iWD Registry”)

World’s first global Wilson’s Registry will provide an international platform for sharing real-world information about Wilson’s disease Registry expected to include 500 individuals affected by this rare disease Paris, France…

Minesh KothariAugust 8, 2022

Company News

Dr. Naseem Amin, Chief Executive Officer at Orphalan, discusses the announcement of the FDA approval of Cuvrior™

Dr. Naseem Amin, Chief Executive Officer at Orphalan, discusses the announcement of the FDA approval of Cuvrior™ in this video: https://www.youtube.com/watch?v=Yu2WsUwtayE

adminMay 3, 2022

Press Release

Orphalan announces FDA approval of Cuvrior™ for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine

Orphalan announces FDA approval of Cuvrior™ for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine. Paris, France 2 May 2022 – Orphalan…

adminMay 2, 2022

Press Release

Orphalan Speaks to Chair of Wilson’s Disease Patient Registry to Celebrate Rare Disease Day

Conversation between Omar Kamlin, Senior Medical Director at Orphalan SA and Prof Pramod Mistry, MBBS, PhD, MA, MD, Director of Yale Lysosomal Disease Center and Gaucher Disease Treatment Center at…

Minesh KothariFebruary 28, 2022

Press Release

Orphalan strengthens its management team with two key appointments

Paris, France 1 February 2022 – Orphalan SA, a Company that identifies, develops, and delivers therapies worldwide for orphan diseases, today announces two new appointments to the management team. Tim…

Minesh KothariFebruary 1, 2022

Company News

Discover More

Latest News

Why We Should Care About Rare Disease Research – Life Science Leader

Orphalan announces US commercial launch of Cuvrior™ for the treatment of Wilson disease

Podcast: Naseem Amin, Orphalan CEO, discusses Wilson’s Disease and the potential advancements in its treatments on DNA Today

Orphalan announces publication of results from the CHELATE trial in The Lancet Gastroenterology & Hepatology

Orphalan announces enrolment of the first five patients in the International Wilson’s Disease Patient Registry (“iWD Registry”)

Dr. Naseem Amin, Chief Executive Officer at Orphalan, discusses the announcement of the FDA approval of Cuvrior™

Orphalan announces FDA approval of Cuvrior™ for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine

Orphalan Speaks to Chair of Wilson’s Disease Patient Registry to Celebrate Rare Disease Day

Orphalan strengthens its management team with two key appointments

Find out more about Orphalan, who we are and what we do

See our research

Contact Us

Global Headquarters

Legal

Useful Links